:A rare non-conservative substitution (G84E) in the HOXB13 gene has been shown to be associated with risk of prostate cancer.
READ FULL ARTICLE
From cebp.aacrjournals.org
A rare non-conservative substitution (G84E) in the HOXB13 gene was found to be associated with an increased risk for prostate cancer and other malignancies in male patients, according to a study published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants included 9,012 male patients in the Mayo Clinic Biobank (MCB). DNA samples were genotyped to calculate the frequency of the G84E variant and its relationship with malignancies and patients completed questionnaires regarding medical history and family history of cancer.
Out of the 9,012 males, 49 were carriers of the G84E mutation (0.5%) and 31% (n = 2,595) of patients were diagnosed with cancer (51.1% of which were G84E carriers and 30.6% were non-carriers (P=0.004).
The G84E mutation was most frequently found in males with prostate cancer compared to males without cancer (P0.0001). The authors observed that G84E was more common in patients with bladder cancer and leukemia (P=0.06 and P=0.01, respectively). Male patients who were G84E mutation carriers were more prone to having a family history of prostate cancer in a first degree relative (36.2%) compared with non-carriers (16.0%, P=0.0003).
The study suggests future research focus on understanding the role of the HOXB13 G84E mutation in malignancies and its novel association with leukemia and bladder cancer.
:A rare non-conservative substitution (G84E) in the HOXB13 gene has been shown to be associated with risk of prostate cancer.
READ FULL ARTICLE
From cebp.aacrjournals.org
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.